Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News vTv Therapeutics Inc VTVT

Healthcare Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of... see more

Recent & Breaking News (NDAQ:VTVT)

vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results

Business Wire August 2, 2017

vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference

Business Wire July 13, 2017

vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions

Business Wire June 11, 2017

vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions

Business Wire June 8, 2017

vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease

Business Wire June 1, 2017

vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results

Business Wire May 3, 2017

vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences

Business Wire March 10, 2017

vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights

Business Wire February 27, 2017

vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes

Business Wire December 14, 2016

New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego

Business Wire November 16, 2016

Horizon Technology Finance Leads $25 Million Venture Loan Facility for vTv Therapeutics

GlobeNewswire November 15, 2016

vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences

Business Wire November 10, 2016

vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights

Business Wire November 2, 2016

vTv Therapeutics to Present at Peptide Therapeutics Symposium

Business Wire October 24, 2016

vTv Therapeutics to Present at Neuro Advance Boston

Business Wire October 3, 2016

vTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference

Business Wire September 8, 2016

vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease

Business Wire September 7, 2016

vTv Therapeutics to Present at the International Psychogeriatric Association International Congress

Business Wire September 2, 2016

vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

Business Wire August 16, 2016

vTv Therapeutics Announces Positive Initial Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes

Business Wire August 10, 2016